Paliperidone ER vs Olanzapine for Treatment-Resistant Schizophrenia
Zachary Davis. Mr. Davis has no financial relationships with companies related to this material.
Zachary Davis. Mr. Davis has no financial relationships with companies related to this material.
Sahil Munjal, MD. Dr. Munjal has no financial relationships with companies related to this material.
Charles DeBattista, MD
Professor of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
Dr. DeBattista has reported receiving research funding from Relmada, Compass, Janssen, Biolite, Myriad, Neurocentia, Beckley, and Sage, and has served as a consultant for Abvie, Sage, and Corcept. This article was reviewed by Dr. Aiken, Editor-in-Chief, who has concluded that there is no evidence of commercial bias in this educational activity.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.